People often get immunotherapy as a treatment for cancer. These immunotherapy treatments can be effective, but they may cause your immune system to have an unnatural response. Your body, as a result ...

For patients with lymphoma or multiple myeloma, speaking up about symptoms of cytokine release syndrome can be lifesaving. It’s important for patients receiving bispecific antibodies for lymphoma or ...

While the use of chimeric antigen receptor (CAR) T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to ...

Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...

A high cytokine cluster was identified that was linked to more severe disease and high concentrations of anti-inflammatories such as IL-10, IL-2R, TNF-RII, and sTNFr1. Patients with sepsis with high ...

CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases. The review, encompassing 19 studies, reveals a high incidence of CRS in patients with ...

Please provide your email address to receive an email when new articles are posted on . Treatment with siltuximab following CAR-T reduced severity of CRS and ICANS. A phase 2 prospective study is ...

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...

The transition from preclinical development to clinical trials is a critical, yet high-risk stage in drug development, with approximately 89% of drugs failing to progress through all phases of ...